Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00470366 · OUTCOME

Rate of Complete Response

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors · Source last updated 2017-11-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
3 years

What was measured

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions

Groups in this outcome

Paclitaxel, Ifosfamide, and Cisplatin

-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles. pegfilgrastim cisplatin ifosfamide paclitaxel

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Paclitaxel, Ifosfamide, and Cisplatin56

Reported measurements

Source class 1

Complete Response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Paclitaxel, Ifosfamide, and Cisplatin38Not reportedNot reportedNot reportedNot reported

PR-Negative

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Paclitaxel, Ifosfamide, and Cisplatin7Not reportedNot reportedNot reportedNot reported

Incomplete Response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Paclitaxel, Ifosfamide, and Cisplatin11Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        38
      title
      Complete Response
    2. measurements
      1. group Id
        OG000
        value
        7
      title
      PR-Negative
    3. measurements
      1. group Id
        OG000
        value
        11
      title
      Incomplete Response
denoms
  1. counts
    1. group Id
      OG000
      value
      56
    units
    Participants
description
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions
groups
  1. description
    -Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles. pegfilgrastim cisplatin ifosfamide paclitaxel
    id
    OG000
    title
    Paclitaxel, Ifosfamide, and Cisplatin
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
3 years
title
Rate of Complete Response
type
PRIMARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice